Latest Market Regulation News

Piedmont Lithium has updated the timetable for its merger with Sayona Mining, setting key dates for shareholder votes, trading suspensions, and the final merger effective date in August 2025.

Rhythm Biosciences has responded to an ASX price query following a sudden surge in its share price and trading volume, confirming no undisclosed information is driving the activity.

X2M Connect Limited’s X2MO securities have been suspended from ASX trading due to non-compliance with listing rules, raising questions about the company’s regulatory standing and next steps.

BirdDog Technology Limited reported a 6.9% increase in quarterly sales to A$4.3 million, driven by the successful launch of two next-generation broadcast products and a strong cash position ahead of a planned share buy-back.

FinTech Chain Limited has requested suspension of its shares from ASX trading to enable its removal from the official list, marking a significant shift for the fintech company.

Resource Development Group Limited has been suspended from ASX trading following the appointment of voluntary administrators, reflecting serious financial distress and regulatory breaches.

Rewardle Holdings Limited remains suspended from ASX trading due to prolonged delays in lodging financial reports, with the exchange warning of imminent delisting unless compliance is demonstrated by mid-September.

G50 Corp Limited attributes its recent share price jump to earlier announcements about a new precious metals discovery, confirming no undisclosed information is driving the trading activity.

Lumos Diagnostics Holdings Limited has had its ASX trading suspension lifted following news of a strategic material agreement, signaling potential growth ahead.

Lumos Diagnostics has voluntarily suspended its ASX trading pending a market announcement about strategic agreements, signaling potential shifts in its business trajectory.

Bowen Coking Coal Limited has had its ASX trading suspension lifted following its disclosure on funding efforts amid challenging market conditions. The company confirmed compliance with ASX rules, paving the way for immediate reinstatement.

Alterity Therapeutics has responded to an ASX inquiry about its recent share price and volume spike, confirming no undisclosed information but highlighting imminent clinical data releases and investor roadshows as possible drivers.